Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 17 peer-reviewed journal articles Updated
Neurology

How Parkinson's Progresses: Subtypes and Stages

At a Glance

Parkinson's progression varies by subtype, with Tremor Dominant (TD) generally progressing slower than Postural Instability and Gait Difficulty (PIGD). Doctors use the Hoehn and Yahr scale to track five stages of physical decline, though research shows many patients remain in the independent Stage 2 for over a decade.

One of the most common questions after a Parkinson’s diagnosis is “how fast will this happen?” While every journey is unique, medical research has identified specific patterns and stages that help doctors and patients understand what to expect. Progression in Parkinson’s is generally measured in years and decades, not weeks [1].

Understanding Clinical Subtypes

Researchers have identified two primary clinical “subtypes” of Parkinson’s. Knowing your subtype can help you prepare for the specific challenges you might face [2].

1. Tremor Dominant (TD)

As the name suggests, the main symptom for this group is a rest tremor.

  • Outlook: TD is generally associated with a slower progression and a lower risk of early cognitive decline [3][4].
  • Unique Feature: People with this subtype often have better compensatory mechanisms in the brain, meaning their brain is better at “working around” the dopamine loss [5].

2. Postural Instability and Gait Difficulty (PIGD)

This subtype is characterized more by balance issues and walking difficulties than by tremors [6].

  • Outlook: PIGD can sometimes progress more quickly than the TD subtype [2].
  • Key Risks: This group has a higher risk of falls and may experience more non-motor symptoms like sleep disturbances, fatigue, and urinary issues [7][6].

The Hoehn and Yahr Scale

Doctors use the Hoehn and Yahr (H&Y) scale to track how the disease is affecting your physical function. It is important to know that many patients remain in the early stages for the majority of their lives [8].

Stage Key Characteristics Typical Duration & Outlook
Stage 1 Symptoms are on only one side of the body. Median time in this stage is about 11 months [8]. Minimal or no functional disability [9].
Stage 2 Symptoms are on both sides, but balance is still good. Median duration is about 11.7 years [8]. Most patients spend the bulk of their journey in this stage.
Stage 3 Balance is impaired (postural instability). Still physically independent; marks the transition to needing more fall prevention strategies [9].
Stage 4 Severe disability; symptoms are very restrictive. May still walk or stand unassisted but needs help with many daily tasks [10].
Stage 5 Confined to a wheelchair or bed unless assisted. This is an advanced stage that only a smaller percentage of patients ever reach [11][12].

Factors That Influence Your Path

While these stages and subtypes provide a general map, modern treatments like Levodopa and Deep Brain Stimulation (DBS) have significantly extended the amount of time patients remain in the early, independent stages [13][14].

  • The Power of Early Action: Engaging in high-intensity exercise and specialized physical therapy early in your diagnosis is one of the best ways to delay the progression of balance and walking issues [15][16].
  • Variability: It is common for someone to be at Stage 2 for 15 or 20 years. Your “biological” age and overall health play a huge role in your resilience [17].

It is important to remember that many people stay in the early stages (1 and 2) for a decade or more, and advancements in treatment continue to improve the quality of life at every stage [1][8].

Common questions in this guide

What are the different subtypes of Parkinson's disease?
Research identifies two primary clinical subtypes: Tremor Dominant (TD) and Postural Instability and Gait Difficulty (PIGD). TD is characterized by resting tremors and often progresses slower, while PIGD involves more balance and walking issues and may progress somewhat faster.
What is the Hoehn and Yahr scale?
The Hoehn and Yahr scale is a clinical tool used to track the progression of Parkinson's symptoms and physical disability. It divides the disease into five stages, ranging from Stage 1 (symptoms on one side only) to Stage 5 (requiring a wheelchair or being bedridden).
How long does each stage of Parkinson's last?
Research suggests that Stage 2, where symptoms affect both sides of the body but balance remains intact, is typically the longest phase. The median duration for this stage is approximately 11.7 years, during which patients usually remain physically independent.
Can I slow down the progression of Parkinson's?
Yes, high-intensity exercise and specialized physical therapy initiated early after diagnosis are considered some of the best ways to delay the onset of balance and walking difficulties. Modern treatments like Levodopa and Deep Brain Stimulation also help extend the time patients spend in early, independent stages.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my current symptoms, do I fit the 'Tremor Dominant' or 'PIGD' subtype, and how does that influence my long-term care plan?
  2. 2.What specific milestones should we be watching for that would indicate I am moving from Stage 1 to Stage 2 on the Hoehn and Yahr scale?
  3. 3.How does my specific subtype affect the likelihood of me developing cognitive or balance issues in the next 5-10 years?
  4. 4.Are there particular exercises or physical therapies you recommend now to delay the progression of gait and balance difficulties?
  5. 5.How often will you reassess my H&Y stage to monitor the rate of my progression?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

Related questions

Do All Parkinson's Patients Need a Wheelchair?Does Parkinson's Disease Affect Life Expectancy?Tremor Dominant Parkinson's: How Fast Does It Progress?

References

References (17)
  1. 1

    Levodopa-induced dyskinesia: clinical features, incidence, and risk factors.

    Tran TN, Vo TNN, Frei K, Truong DD

    Journal of neural transmission (Vienna, Austria : 1996) 2018; (125(8)):1109-1117 doi:10.1007/s00702-018-1900-6.

    PMID: 29971495
  2. 2

    Neutrophil-to-Lymphocyte Ratio as a Biomarker for Motor Subtypes in Idiopathic Parkinson's Disease.

    Awan R, Tahir O, Noor Ul Hadi S, et al.

    Cureus 2025; (17(1)):e77440 doi:10.7759/cureus.77440.

    PMID: 39949444
  3. 3

    The role of motor subtypes in modulating neuropsychiatric and cognitive function in Parkinson's disease: A group-stratified mediation analysis.

    Chien CY, Tan CH, Hong WP, et al.

    Journal of psychiatric research 2026; (192()):352-359 doi:10.1016/j.jpsychires.2025.10.069.

    PMID: 41197217
  4. 4

    Clinical features and progression of Parkinson's disease with LRRK2 variants: A prospective study.

    Song T, Zhou X, Wang C, et al.

    Annals of clinical and translational neurology 2025; (12(1)):34-42 doi:10.1002/acn3.52244.

    PMID: 39529459
  5. 5

    Functional connectivity alterations in the motor and fronto-parietal network relate to behavioral heterogeneity in Parkinson's disease.

    Vervoort G, Alaerts K, Bengevoord A, et al.

    Parkinsonism & related disorders 2016; (24()):48-55.

    PMID: 26924603
  6. 6

    Biomechanical analysis of sit-to-walk in different Parkinson's disease subtypes.

    Pelicioni PHS, Pereira MP, Lahr J, et al.

    Clinical biomechanics (Bristol, Avon) 2020; (75()):105010 doi:10.1016/j.clinbiomech.2020.105010.

    PMID: 32335472
  7. 7

    Non-motor symptoms in early Parkinson's disease with different motor subtypes and their associations with quality of life.

    Huang X, Ng SY, Chia NS, et al.

    European journal of neurology 2019; (26(3)):400-406 doi:10.1111/ene.13803.

    PMID: 30175887
  8. 8

    [Hoehn & Yahr scale and MDS-UPDRS Part 3 progression in Parkinson's disease patients: retrospective natural history study using a disease registry].

    Watanabe T, Naoi I, Obata R, et al.

    Rinsho shinkeigaku = Clinical neurology 2025; (65(12)):865-872 doi:10.5692/clinicalneurol.cn-002132.

    PMID: 41242735
  9. 9

    Evaluation of dysphagia in different phenotypes of early and idiopathic Parkinsonism.

    Mohamed AB, Mohamed GF, Elnady HM, et al.

    The Egyptian journal of neurology, psychiatry and neurosurgery 2018; (54(1)):28 doi:10.1186/s41983-018-0031-1.

    PMID: 30416335
  10. 10

    Profile of Independence in Activities of Daily Living Among Patients With Parkinson's Disease: A Retrospective Observational Study.

    Yokoi K, Kawasaki I, Takeda A, et al.

    The American journal of occupational therapy : official publication of the American Occupational Therapy Association 2025; (79(3)) doi:10.5014/ajot.2025.050882.

    PMID: 40162911
  11. 11

    Dysphagia predicts poor outcome in late-stage Parkinson's disease.

    Fabbri M, Coelho M, Abreu D, et al.

    Parkinsonism & related disorders 2019; (64()):73-81 doi:10.1016/j.parkreldis.2019.02.043.

    PMID: 30902528
  12. 12

    Prevalence of Late-Stage Parkinson's Disease in the US Healthcare System: Insights from TriNetX.

    De Jesus S, Daya A, Blumberger L, et al.

    Movement disorders : official journal of the Movement Disorder Society 2024; (39(9)):1592-1601 doi:10.1002/mds.29900.

    PMID: 38962960
  13. 13

    Deep Brain Stimulation in Parkinson's Disease.

    Malek N

    Neurology India 2019; (67(4)):968-978 doi:10.4103/0028-3886.266268.

    PMID: 31512617
  14. 14

    Long-term outcomes of deep brain stimulation in severe Parkinson's disease utilizing UPDRS III and modified Hoehn and Yahr as a severity scale.

    Kahn L, Mathkour M, Lee SX, et al.

    Clinical neurology and neurosurgery 2019; (179()):67-73 doi:10.1016/j.clineuro.2019.02.018.

    PMID: 30851616
  15. 15

    Exercise as a multitarget therapy: modulating myokines, neurotrophins, and inflammation in Parkinson's disease.

    Li WQ, Yang JH, Liu LL, et al.

    Frontiers in aging neuroscience 2025; (17()):1580029 doi:10.3389/fnagi.2025.1580029.

    PMID: 40933823
  16. 16

    A longitudinal study on physical activity in early Parkinson's disease.

    Ng SY, Naheed D, Saffari ES, et al.

    Journal of Parkinson's disease 2025; (15(8)):1524-1528 doi:10.1177/1877718X251380487.

    PMID: 41042907
  17. 17

    Increased Mortality in Young-Onset Parkinson's Disease.

    Hustad E, Myklebust TÅ, Gulati S, Aasly JO

    Journal of movement disorders 2021; (14(3)):214-220 doi:10.14802/jmd.21029.

    PMID: 34315208

This guide explains the typical progression and staging of Parkinson's disease for educational purposes. Disease progression varies significantly by individual, and your neurologist is the best resource for your specific prognosis.

Get notified when new evidence is published on Parkinson's Disease.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.